Investigator Profile: Meghan R. Flanagan, MD, MPH

Meghan R. Flanagan, MD, MPH

Assistant Professor, Division of General Surgery

I am a breast surgical oncologist with health services/outcomes, clinical trial and translational research interests. My research is often driven by questions that arise as I treat my patients, and my desire to fill gaps in knowledge so I can ensure I am offering the most recent, best evidence based treatments to my patients. My research spans from improving management of breast cancer locoregional recurrence and high risk lesions such as lobular neoplasia to improving the understanding of how alterations in genes involved in the estrogen hormone biosynthetic pathway can impact breast cancer recurrence and survival.

Collaborators

Hannah Linden, Breast Medical Oncology, UW/FHCC
Sarah Nyante, Epidemiologist, University of North Carolina
Nima Sharifi, GU Medical Oncology, University of Miami
Elizabeth Parker, Breast Pathology, UW/FHCC
Daniel Reiter, Breast Pathology, UW/FHCC
VK Gadi, Breast Medical Oncology, University of Illinois, Chicago
Isaac Stein, Plastic Surgery, UW/FHCC
Suzanne Inchauste, Plastic Surgery, UW/FHCC
Elahe Mostaghel, Medical Oncology, VA/UW/FHCC

Funding

6/5/2019 – 6/4/2021 National Cancer Institute (5P30 CA015704-40)
Title: Utilization of decision analysis to inform design of a clinical trial for management of high-risk breast lesions
Principal investigator: D. Gary Gilliland, MD, PhD (2019-2020); Thomas Lynch, MD (2020-2021)
Role: Co-investigator
Funding: $97,000

2/2020 – CurrentSwim Across America Foundation
Title: Association of HSD3B1 (1245C) genotype with recurrence among post-menopausal women with estrogen receptor-positive, HER2-negative breast cancer.
Principal investigator: Meghan Flanagan, MD, MPH
Role: Principal investigator
Funding: $116,666

2/1/2021 – 1/1/2023 National Cancer Institute (5P30 CA015704-40)
Title: Association of HSD3B1 genotype with response to preoperative endocrine therapy among postmenopausal women with estrogen-receptor positive (ER+) HER2/neu-negative (HER2-) invasive ductal carcinoma (IDC)
Principal Investigator: Thomas Lynch, MD
Role: New Investigator Award Recipient
Funding: $124,400

4/2/2021 – 4/1/2022Dolsen Family Fund
Title: Lymphatic Microsurgical Preventive Healing Approach
Principal Investigator: Meghan Flanagan, MD, MPH
Role: Principal investigator
Funding: $50,000

4/8/2021 – 6/30/2023Kuni Foundation Imagination Grants for Cancer Research
Title: Using spatial genomics to predict progression of lobular carcinoma in situ to invasive breast cancer
Principal Investigator: Meghan Flanagan, MD, MPH
Role: Principal investigator
Funding: $75,000

8/1/2022 – 7/31/2026Department of Defense (W81XWH2220003)
Title: Prevention of lethal metastatic breast cancer by identifying and eradicating clinically relevant disseminated tumor cells
Principal Investigators: Cyrus Ghajar, PhD; Christopher Li, MD, PhD; Stanley Riddle, MD
Role: Co-investigator
Funding: $39,262,160

7/1/2023 – 6/30/2024National Institutes of Health (R21 CA270625-01)
Title: Breast cancer neoadjuvant endocrine therapy during the Covid-19 pandemic: opportunity for a new treatment paradigm
Principal Investigator: Sarah Nyante, PhD
Role: Co-investigator
Funding: $181,741

6/22/2023 –Perimeter Medical Imaging AI Inc. (Protocol PER-19-04)
Title: A prospective, multicenter, randomized, double-arm trial to determine the impact of the SELENE system on positive margin rates in breast conservation surgery
Role: Site principal investigator

6/26/2023 –Intuitive (Protocol ISI dV SP – NSM-01)
Title: A prospective, multicenter, randomized controlled trial of the da Vinci® SP™ surgical system vs open surgery in nipple sparing mastectomy procedures
Role: Co-investigator

Significant Publications